QQQ   358.52 (+0.17%)
AAPL   175.68 (+0.51%)
MSFT   315.92 (-0.34%)
META   299.71 (+0.21%)
GOOGL   130.77 (+0.40%)
AMZN   131.57 (+1.90%)
TSLA   245.69 (+0.33%)
NVDA   420.02 (+0.94%)
NIO   8.37 (-1.88%)
BABA   87.08 (-1.38%)
AMD   96.77 (+0.59%)
T   15.10 (-0.13%)
F   12.58 (+1.21%)
MU   68.04 (-1.22%)
CGC   0.93 (+10.44%)
GE   111.58 (+0.30%)
DIS   80.85 (-0.49%)
AMC   8.19 (+7.48%)
PFE   32.78 (+0.28%)
PYPL   58.74 (+1.49%)
NFLX   384.18 (+1.15%)
QQQ   358.52 (+0.17%)
AAPL   175.68 (+0.51%)
MSFT   315.92 (-0.34%)
META   299.71 (+0.21%)
GOOGL   130.77 (+0.40%)
AMZN   131.57 (+1.90%)
TSLA   245.69 (+0.33%)
NVDA   420.02 (+0.94%)
NIO   8.37 (-1.88%)
BABA   87.08 (-1.38%)
AMD   96.77 (+0.59%)
T   15.10 (-0.13%)
F   12.58 (+1.21%)
MU   68.04 (-1.22%)
CGC   0.93 (+10.44%)
GE   111.58 (+0.30%)
DIS   80.85 (-0.49%)
AMC   8.19 (+7.48%)
PFE   32.78 (+0.28%)
PYPL   58.74 (+1.49%)
NFLX   384.18 (+1.15%)
QQQ   358.52 (+0.17%)
AAPL   175.68 (+0.51%)
MSFT   315.92 (-0.34%)
META   299.71 (+0.21%)
GOOGL   130.77 (+0.40%)
AMZN   131.57 (+1.90%)
TSLA   245.69 (+0.33%)
NVDA   420.02 (+0.94%)
NIO   8.37 (-1.88%)
BABA   87.08 (-1.38%)
AMD   96.77 (+0.59%)
T   15.10 (-0.13%)
F   12.58 (+1.21%)
MU   68.04 (-1.22%)
CGC   0.93 (+10.44%)
GE   111.58 (+0.30%)
DIS   80.85 (-0.49%)
AMC   8.19 (+7.48%)
PFE   32.78 (+0.28%)
PYPL   58.74 (+1.49%)
NFLX   384.18 (+1.15%)
QQQ   358.52 (+0.17%)
AAPL   175.68 (+0.51%)
MSFT   315.92 (-0.34%)
META   299.71 (+0.21%)
GOOGL   130.77 (+0.40%)
AMZN   131.57 (+1.90%)
TSLA   245.69 (+0.33%)
NVDA   420.02 (+0.94%)
NIO   8.37 (-1.88%)
BABA   87.08 (-1.38%)
AMD   96.77 (+0.59%)
T   15.10 (-0.13%)
F   12.58 (+1.21%)
MU   68.04 (-1.22%)
CGC   0.93 (+10.44%)
GE   111.58 (+0.30%)
DIS   80.85 (-0.49%)
AMC   8.19 (+7.48%)
PFE   32.78 (+0.28%)
PYPL   58.74 (+1.49%)
NFLX   384.18 (+1.15%)
NASDAQ:PULM

Pulmatrix (PULM) Stock Forecast, Price & News

$2.12
-0.05 (-2.30%)
(As of 02:40 PM ET)
Compare
Today's Range
$2.10
$2.15
50-Day Range
$2.16
$2.70
52-Week Range
$2.10
$4.49
Volume
4,920 shs
Average Volume
22,160 shs
Market Capitalization
$7.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Pulmatrix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
373.9% Upside
$10.00 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Pulmatrix in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.38) to ($4.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars


PULM stock logo

About Pulmatrix (NASDAQ:PULM) Stock

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

PULM Price History

PULM Stock News Headlines

StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company
Decades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>
Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
H.C. Wainwright Remains a Buy on Pulmatrix (PULM)
Pulmatrix Supports World Asthma Day 2023
See More Headlines
Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PULM
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+360.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,840,000.00
Net Margins
-253.24%
Pretax Margin
-253.24%

Debt

Sales & Book Value

Annual Sales
$6.07 million
Book Value
$8.55 per share

Miscellaneous

Free Float
3,520,000
Market Cap
$7.92 million
Optionable
Optionable
Beta
0.75
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Teofilo David Raad MBA (Age 53)
    Pres, CEO & Director
    Comp: $772.7k
  • Mr. Peter Ludlum CMA (Age 68)
    MBA, Interim CFO and Principal Accounting & Financial Officer
    Comp: $398.58k
  • Dr. Margaret M. Wasilewski M.D. (Age 66)
    Chief Medical Officer
    Comp: $585.84k
  • Dr. Alexander M. Klibanov Ph.D. (Age 73)
    Founder













PULM Stock - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings
or view top-rated stocks.

What is Pulmatrix's stock price forecast for 2023?

1 analysts have issued 1-year price objectives for Pulmatrix's shares. Their PULM share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 360.8% from the stock's current price.
View analysts price targets for PULM
or view top-rated stocks among Wall Street analysts.

How have PULM shares performed in 2023?

Pulmatrix's stock was trading at $3.88 at the beginning of 2023. Since then, PULM shares have decreased by 44.1% and is now trading at $2.17.
View the best growth stocks for 2023 here
.

Are investors shorting Pulmatrix?

Pulmatrix saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 2,700 shares, a drop of 20.6% from the August 15th total of 3,400 shares. Based on an average trading volume of 12,900 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's shares are sold short.
View Pulmatrix's Short Interest
.

When is Pulmatrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our PULM earnings forecast
.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) posted its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.23) by $0.19. The biotechnology company earned $1.84 million during the quarter, compared to the consensus estimate of $1.51 million. Pulmatrix had a negative trailing twelve-month return on equity of 60.14% and a negative net margin of 253.24%.

When did Pulmatrix's stock split?

Shares of Pulmatrix reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $2.17.

How much money does Pulmatrix make?

Pulmatrix (NASDAQ:PULM) has a market capitalization of $7.92 million and generates $6.07 million in revenue each year. The biotechnology company earns $-18,840,000.00 in net income (profit) each year or ($4.85) on an earnings per share basis.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The official website for the company is www.pulmatrix.com. The biotechnology company can be reached via phone at (781) 357-2333, via email at rclarke@pulmatrix.com, or via fax at 707-525-9906.

This page (NASDAQ:PULM) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -